In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy
Autor: | Yi Han, Yong Chen, Ting He, Man-Wen Jin, Wei-Qin Yang, Lei Chen |
---|---|
Rok vydání: | 2011 |
Předmět: |
Male
medicine.medical_specialty Cardiotonic Agents Cardiac fibrosis Diastole Down-Regulation Blood Pressure Cardiomegaly Rats Sprague-Dawley Fibrosis In vivo Internal medicine Natriuretic Peptide Brain medicine Animals Pharmacology (medical) Myocytes Cardiac PPAR alpha RNA Messenger Aldosterone PPAR-beta Cells Cultured Pharmacology Pressure overload Heart Failure Endothelin-1 business.industry Interleukin-6 Tumor Necrosis Factor-alpha Hemodynamics General Medicine Fibroblasts medicine.disease Rats Up-Regulation Blood pressure Endocrinology Heart failure Myocardial fibrosis Quercetin Collagen Cardiology and Cardiovascular Medicine business |
Zdroj: | Cardiovascular drugs and therapy. 26(2) |
ISSN: | 1573-7241 |
Popis: | To investigate the in vivo and in vitro protective effects of pentamethylquercetin (PMQ), a member of polymethoxy flavonoids (PMFs), on cardiac hypertrophy. An in vivo cardiac hypertrophy model established by abdominal aorta banding technique in rats was treated with PMQ in increasing dosages (2.5, 5, and 10 mg·kg−1·d−1). An in vitro cardiomyocyte hypertrophy model was induced by treating neonatal cardiomyocytes with endothelin-1 (ET-1, 0.1 μM). An in vitro fibrosis model was developed in cardiac fibroblasts by aldosterone (Ald, 20 nM) and treated with PMQ (0.3, 1, 3 and 10 μM). Hemodynamic, morphological, histological, and biochemical changes were evaluated at corresponding time points. The abdominal aorta constriction (AAC) rats demonstrated a significantly elevated blood pressure and profound systolic and diastolic cardiac dysfunction. The resultant cardiac hypertrophy and heart failure were characterized by a significant increase in the heart and lung indices (3.51 ± 0.30 vs 2.35 ± 0.24, 5.58 ± 0.85 vs 3.94 ± 0.54; both P |
Databáze: | OpenAIRE |
Externí odkaz: |